satralizumab: Clinical Trials

9 trials of satralizumab, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	9	Completed 5, Active not recruiting 2, Recruiting 1, Terminated 1

Follow satralizumab: new trials by email Literature Review of satralizumab trials Research Report on satralizumab

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab - Neuromyelitis Optica Spectrum Disorder, NMOSD	Phase 3	Recruiting	Hoffmann-La Roche	8	2026-05-06	2026-10-01
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease	Phase 3	Completed	Hoffmann-La Roche	127	2023-11-15	2026-08-12
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease Satralizumab, Placebo - Thyroid Eye Disease, TED	Phase 3	Completed	Hoffmann-La Roche	131	2023-10-26	2026-07-31
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis Satralizumab, Placebo - NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis	Phase 3	Active not recruiting	Hoffmann-La Roche	122	2022-09-27	2026-10-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Satralizumab, Placebo - Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)	Phase 3	Active not recruiting	Hoffmann-La Roche	139	2022-08-30	2026-10-16
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Satralizumab, Placebo - Generalized Myasthenia Gravis	Phase 3	Terminated	Hoffmann-La Roche	188	2021-10-19	2025-02-28
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF) - Neuromyelitis Optica Spectrum Disorder	Phase 3	Completed	Hoffmann-La Roche	119	2021-03-02	2024-12-27
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Satralizumab, Placebo - Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)	Phase 3	Completed	Hoffmann-La Roche	95	2014-08-05	2023-03-01
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) Satralizumab, Placebo, Baseline Treatment - Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)	Phase 3	Completed	Hoffmann-La Roche	85	2014-02-20	2023-04-18

Conditions studied

Sponsors

Countries

Results publications

NIH funding